Early life adversity and serotonin transporter gene variation interact at the level of the adrenal gland to affect the adult hypothalamo-pituitary-adrenal axis

Translational Psychiatry

Volumn 4, Issue 7, 2014, Pages

  Van Der Doelen, R H A ^a   Deschamps, W ^a   D'Annibale, C ^a   Peeters, D ^a   Wevers, R A ^a   Zelena, D ^b   Homberg, J R ^a   Kozicz, T ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GLUCOCORTICOID; SEROTONIN TRANSPORTER;

ADRENAL GLAND; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HYPOPHYSIS; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MATERNAL DEPRIVATION; NONHUMAN; PROMOTER REGION; RAT; AGE; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; TRANSGENIC RAT;

ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; AGE FACTORS; ANIMALS; CORTICOSTERONE; DISEASE MODELS, ANIMAL; GENE-ENVIRONMENT INTERACTION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MATERNAL DEPRIVATION; PITUITARY-ADRENAL SYSTEM; RATS; RATS, TRANSGENIC; RECEPTORS, CORTICOTROPIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRESS, PSYCHOLOGICAL;

EID: 84928011808     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.57     Document Type: Article

References (61)

1. Murphy SE, Norbury R, O'Sullivan U, Cowen PJ, Harmer CJ. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry. 2009; 194 5-40.
2. Simmons AN, Arce E, Lovero KL, Stein MB, Paulus MP. Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int J Neuropsychopharmacol. 2009; 12: 1009-1020.
3. Windischberger C, Lanzenberger R, Holik A, Spindelegger C, Stein P, Moser U, et al. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage. 2010; 49: 1161-1170.
4. McCabe C, Mishor Z. Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. Neuroimage. 2011; 57 1317-1323.
5. Takahashi H, Yahata N, Koeda M, Takano A, Asai K, Suhara T, et al. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage. 2005; 27: 991-1001.
6. Miskowiak K, Papadatou-Pastou M, Cowen PJ, Goodwin GM, Norbury R, Harmer CJ. Single dose antidepressant administration modulates the neural processing of self-referent personality trait words. Neuroimage. 2007; 37: 904-911.
7. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. Short-Term antidepressant treatment and facial processing. Functional magnetic resonance imaging study. Br J Psychiatry. 2007; 190: 531-532.
8. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study. Mol Psychiatry. 2008; 13: 1011-1020.
9. Onur OA, Walter H, Schlaepfer TE, Rehme AK, Schmidt C, Keysers C, et al. Noradrenergic enhancement of amygdala responses to fear. Soc Cogn Affect Neurosci. 2009; 4: 119-126.
10. Brühl AB, Jäncke L, Herwig U. Differential modulation of emotion processing brain regions by noradrenergic and serotonergic antidepressants. Psychopharmacology (Berl) 2011; 216: 389-399.
11. Norbury R, Taylor MJ, Selvaraj S, Murphy SE, Harmer CJ, Cowen PJ. Short-Term antidepressant treatment modulates amygdala response to happy faces. Psychopharmacology (Berl) 2009; 206: 197-204.
12. Brühl AB, Kaffenberger T, Herwig U. Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants. Neuropsychopharmacology. 2010; 35: 521-533.
13. Matthews SC, Simmons AN, Strigo IA, Arce E, Stein MB, Paulus MP. Escitalopram attenuates posterior cingulate activity during self-evaluation in healthy volunteers. Psychiatry Res. 2010; 182: 81-87.
14. Anderson IM, McKie S, Elliott R, Williams SR, Deakin JF. Assessing human 5-HT function in vivo with pharmaco-MRI. Neuropharmacology. 2008; 55: 1029-1037.
15. Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ. A meta-Analytic study of changes in brain activation in depression. Hum Brain Mapp. 2008; 29: 683-695.
16. Van Wingen GA, Van Eijndhoven P, Cremers HR, Tendolkar I, Verkes RJ, Buitelaar JK, et al. Neural state and trait bases of mood-incongruent memory formation and retrieval in first-episode major depression. J Psychiatr Res. 2010; 44: 527-534.
17. Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry. 2003; 160: 64-75.
18. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009; 195: 102-108.
19. Gentil V, Zilberman ML, Lobo D, Henna E, Moreno RA, Gorenstein C. Clomipramine-induced mood and perceived performance changes in selected healthy individuals [letter]. J Clin Psychopharmacol. 2007; 27: 314-315.
20. Serretti A, Calati R, Goracci A, Di Simplicio M, Castrogiovanni P, De Ronchi D. Antidepressants in healthy subjects: what are the psychotropic/psychological effects? Eur Neuropsychopharmacol. 2010; 20: 433-453.
21. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000; 48: 830-843.
22. Fu CHY, Williams SCR, Brammer MJ, Suckling J, Kim J, Cleare AJ, et al. Neural responses to happy facial expressions in major depression following antidepressant treatment. Am J Psychiatry. 2007; 164: 599-607.
23. Drevets WC. Translating progress in depression research to the clinic: one step at a time on a very long road. World Psychiatry. 2010; 9: 162.
24. Simplicio D. Short-Term antidepressant administration reduces negative selfreferential processing in the medial prefrontal cortex in subjects at risk for depression. Mol Psychiatry. 2011; 17: 503-510.
25. Cerqueira CT, Almeida JRC, Gorenstein C, Gentil V, Leite CC, Sato JR, et al. Engagement of multifocal neural circuits during recall of autobiographical happy events. Braz J Med Biol Res. 2008; 41: 1076-1085.
26. Cerqueira CT, Almeida JR, Sato JR, Gorenstein C, Gentil V, Leite CC, et al. Cognitive control associated with irritability induction: an autobiographical recall fMRI study. Rev Bras Psiquiatr. 2010; 32: 109-118.
27. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology. 2009; 35: 192-216.
28. Young KD, Erickson K, Nugent AC, Fromm SJ, Mallinger AG, Furey ML, et al. Functional anatomy of autobiographical memory recall deficits in depression. Psychol Med. 2011; 29: 1-13.
29. Lemogne C, Delaveau P, Freton M, Guionnet S, Fossati P. Medial prefrontal cortex and the self in major depression. J Affect Disord. 2012; 136: e1-e11.
30. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971; 9: 97-113.
31. First MB, Spitzer RL, Gibbon M, Willians JBW. Structured Clinical Interview for DSMIV Axis I Disorders (SCID version 2.0). Biometric research Department, New York State Psychiatric Institute: New York, USA, 1995.
32. Weissman MM, Wickramaratne P, Adams P, Wolk S, Verdeli H, Olfson M. Brief screening for family psychiatric history: the family history screen. Arch Gen Psychiatry. 2000; 57: 675-682.
33. Gentil V, Lotufo-Neto F, Andrade L, Cordás T, Bernik M, Ramos R, et al. Clomipramine, a betterreferencedrug for panic/agoraphobia. I. Effectiveness comparison with imipramine. J Psychopharmacol. 1993; 7: 316-324.
34. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007; 151: 737-748.
35. Wong DF, Tauscher J, Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology. 2009; 34: 187-203.
36. Campos A, Gonzalez MA, Amor A. The Spanish version of the Vividness of Visual Imagery Questionnaire: factor structure and internal consistency reliability. Psychol Rep. 2002; 90: 503-506.
37. Spielberger CD, Gorsuch RL, Lushene PR, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto, CA, 1983.
38. Bullmore E, Fadili J, Breakspear M, Salvador R, Suckling J, Brammer M. Wavelets and statistical analysis of functional magnetic resonance images of the human brain. Stat Methods Med Res. 2003; 12: 375-399.
39. Friman O, Borga M, Lundberg P, Knutsson H. Adaptive analysis of fMRI data. Neuroimage. 2003; 19: 837-845.
40. Bullmore E, Brammer M, Williams SC, Rabe-Hesketh S, Janot N, David A, et al. Statistical methods of estimation and inference for functional MR image analysis. Magn Reson Med. 1996; 35: 261-277.
41. Roy M, Harvey PO, Berlim MT, Mamdani F, Beaulieu MM, Turecki G, et al. Medial prefrontal cortex activity during memory encoding of pictures and its relation to symptomatic improvement after citalopram treatment in patients with major depression. J Psychiatry Neurosci. 2010; 35: 152-162.
42. López-Solà M, Pujol J, Hernández-Ribas R, Harrison BJ, Contreras-Rodríguez O, Soriano-Mas C, et al. Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder. Neuropsychopharmacology. 2010; 35 2305-2317.
43. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001; 158 899-905.
44. Canli T, Cooney RE, Goldin P, Shah M, Sivers H, Thomason ME, et al. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport. 2005; 16: 1267-1270.
45. Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, et al. Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study. Neuropsychopharmacology. 2005; 30: 1334-1344.
46. Anand A, Li Y, Wang Y, Gardner K, Lowe MJ. Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. J Neuropsychiatry Clin Neurosci. 2007; 19: 274-282.
47. Moses-Kolko EL, Perlman SB, Wisner KL, James J, Saul AT, Phillips ML. Abnormally reduced dorsomedial prefrontal cortical activity and effective connectivity with amygdala in response to negative emotional faces in postpartum depression. Am J Psychiatry. 2010; 167: 1373-1380.
48. Lemogne C, Mayberg H, Bergouignan L, Volle E, Delaveau P, Lehericy S, et al. Selfreferential processing and the prefrontal cortex over the course of depression: a pilot study. J Affect Disord. 2010; 124: 196-201.
49. Fales CL, Barch DM, Rundle MM, Mintun MA, Mathews J, Snyder AZ, et al. Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression. J Affect Disord. 2009; 112: 206-211.
50. Hsu DT, Langenecker SA, Kennedy SE, Zubieta JK, Heitzeg MM. fMRI BOLD responses to negative stimuli in the prefrontal cortex are dependent on levels of recent negative life stress in major depressive disorder. Psychiatry Res. 2010; 183 202-208.
51. Grefkes C, Wang LE, Eickhoff SB, Fink GR. Noradrenergic modulation of cortical networks engaged in visuomotor processing. Cereb Cortex. 2010; 20: 783-797.
52. Völlm B, Richardson P, McKie S, Elliott R, Deakin JF, Anderson IM. Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli an fMRI study in healthy volunteers. Eur J Neurosci. 2006; 23: 552-560.
53. Fortier E, Noreau A, Lepore F, Boivin M, Perusse D, Rouleau GA, et al. Early impact of 5-HTTLPR polymorphism on the neural correlates of sadness. Neurosci Lett. 2010; 485: 261-265.
54. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulate-Amygdala interactions a genetic susceptibility mechanism for depression. Nat Neurosci. 2005; 8 828-834.
55. Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience. 2009; 164: 300-330.
56. Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson RC, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry. 1998; 155: 373-379.
57. Lemogne C, Bergouignan L, Boni C, Gorwood P, Pelissolo A, Fossati P. Genetics and personality affect visual perspective in autobiographical memory. Conscious Cogn. 2009; 18: 823-830.
58. Tang TZ, DeRubeis RJ, Hollon SD, Amsterdam J, Shelton R, Schalet B. Personality change during depression treatment: a placebo-controlled trial. Arch Gen Psychiatry. 2009; 66: 1322-1330.
59. Anderson IM, McKie S, Elliott R, Williams SR, Deakin JF. Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology. 2008; 55: 1029-1037.
60. de Almeida JR, Phillips ML, Cerqueira CT, Zilberman M, Lobo D, Henna E, et al. Neural activity changes to emotional stimuli in healthy individuals under chronic use of clomipramine. J Psychopharmacol. 2009; 24: 1165-1174.
61. Dumont G, De Visser SJ, Cohen AF, Van Gerven J. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol. 2005; 59: 495-510.